Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Schenk

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
NPJ Precision Oncology|February 5, 2023
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunityEmily K Kleczko, Trista K Hinz, Teresa T Nguyen, et al.
Cell Death and Differentiation|April 1, 2017
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivoEmma M Carrington, Yifan Zhan, Jamie L Brady, et al.
JTO Clinical and Research Reports|February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLCTejas Patil, Alyse Staley, Yunan Nie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter StudyCollin M Blakely, Anatoly Urisman, Matthew A Gubens, et al.
Blood Advances|June 8, 2021
BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropeniaEmma M Carrington, Cynthia Louis, Tobias Kratina, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
NPJ Precision Oncology|February 5, 2023
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunityEmily K Kleczko, Trista K Hinz, Teresa T Nguyen, et al.
Cell Death and Differentiation|April 1, 2017
Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivoEmma M Carrington, Yifan Zhan, Jamie L Brady, et al.
JTO Clinical and Research Reports|February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLCTejas Patil, Alyse Staley, Yunan Nie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2024
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter StudyCollin M Blakely, Anatoly Urisman, Matthew A Gubens, et al.
Blood Advances|June 8, 2021
BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropeniaEmma M Carrington, Cynthia Louis, Tobias Kratina, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Pageof 11